<DOC>
	<DOCNO>NCT00006467</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine ISIS 2503 treat patient advanced metastatic cancer pancreas .</brief_summary>
	<brief_title>Gemcitabine ISIS 2503 Treating Patients With Advanced Metastatic Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine 6-month overall survival rate patient locally advance metastatic adenocarcinoma pancreas treat gemcitabine ISIS 2503 . II . Determine response rate patient treat regimen . III . Assess toxicity regimen patient population . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 8 ISIS 2503 IV continuously day 1-14 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 4 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced metastatic adenocarcinoma pancreas amenable standard curative therapy Duct cell Undifferentiated The following cellular type eligible : Islet cell carcinoma Acinar cell carcinoma Cystadenocarcinoma No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 No underlying disease associate active bleeding Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN AST great 3 time ULN PT PTT normal Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy immunotherapy No concurrent immunotherapy No colonystimulating factor first course therapy Chemotherapy : No prior chemotherapy except radiosensitizing agent use adjuvant set treatment locally advance disease No prior gemcitabine No prior ISIS 2503 No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 25 % great bone marrow No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>